Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

By R. Wong, R. Cheung, Aijaz Ahmed. Hepatology, 2014

695 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/ea665af79d24259f70b5667bcd753305ee5a342a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. R. Loomba
2. Z. Younossi
3. A. Sanyal
4. M. Kudo
5. M. Pinzani
6. C. Estes
7. M. Parola
8. H. Razavi

In Hepatology

1. Z. Younossi
2. R. Loomba
3. A. Sanyal
4. M. Kudo
5. M. Pinzani
6. A. Cheng
7. C. Estes
8. M. Parola

Citations in the corpus

• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “Indeed, in a recent retrospective cohort study that evaluated trends in HCC etiology among adult recipients of liver transplantation (LT) from 2002 to 2012, the number of patients undergoing LT for HCC secondary to nonalcoholic steatohepatitis (NASH) increased by nearly fourfold, whereas the number ”
• Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. (2019, background): “, non-alcoholic steatohepatitis or NASH), is emerging worldwide as the most rapidly growing indication for liver transplantation in HCC patients, with a significant percentage of cases diagnosed in non-cirrhotic patients (Wong et al., 2014; Younes and Bugianesi, 2018).”